UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

COVID-19 Severity Is Tripled in the Diabetes Community: A Prospective Analysis of the Pandemic's Impact in Type 1 and Type 2 Diabetes

Diabetes care, 2021-02, Vol.44 (2), p.526-532

2021

Volltextzugriff (PDF)

Astaxanthin, a natural antioxidant, lowers cholesterol and markers of cardiovascular risk in individuals with prediabetes and dyslipidaemia

Diabetes, obesity & metabolism, 2023-07, Vol.25 (7), p.1985-1994

2023

Volltextzugriff (PDF)

Time in Tight Range for Patients With Type 1 Diabetes: The Time Is Now, or Is It Too Soon?

Diabetes care, 2024-05, Vol.47 (5), p.782-784

2024

Volltextzugriff (PDF)

Incidences of Severe Hypoglycemia and Diabetic Ketoacidosis and Prevalence of Microvascular Complications Stratified by Age and Glycemic Control in U.S. Adult Patients With Type 1 Diabetes: A Real-World Study

Diabetes care, 2019-12, Vol.42 (12), p.2220-2227

2019

Volltextzugriff (PDF)

Risk of new‐onset type 2 diabetes in 600 055 people after COVID‐19: A cohort study

Diabetes, obesity & metabolism, 2022-06, Vol.24 (6), p.1176-1179

2022

Volltextzugriff (PDF)

Past-Month Cannabis Use Among Adults With Diabetes in the U.S., 2021-2022

Diabetes care, 2024-09, Vol.47 (9), p.e67-e69

2024

Volltextzugriff (PDF)

SGLT2 Inhibition Increases Fasting Glucagon but Does Not Restore the Counterregulatory Hormone Response to Hypoglycemia in Participants With Type 1 Diabetes

Diabetes (New York, N.Y.), 2022-03, Vol.71 (3), p.511-519

2022

Volltextzugriff (PDF)

Combination SGLT2 Inhibitor and Glucagon Receptor Antagonist Therapy in Type 1 Diabetes: A Randomized Clinical Trial

Diabetes care, 2024-05

2024

Volltextzugriff (PDF)

Continuous Glucose Monitoring Time Below Range Predicts Impaired Epinephrine Response to Hypoglycemia in Patients With Type 1 Diabetes

Diabetes care, 2024-05, Vol.47 (5), p.e39-e41

2024

Volltextzugriff (PDF)

Efficacy and Safety of the Glucagon Receptor Antagonist RVT-1502 in Type 2 Diabetes Uncontrolled on Metformin Monotherapy: A 12-Week Dose-Ranging Study

Diabetes care, 2020-01, Vol.43 (1), p.161-168

2020

Volltextzugriff (PDF)

Differences between patients with type 1 diabetes with optimal and suboptimal glycaemic control: A real‐world study of more than 30 000 patients in a US electronic health record database

Diabetes, obesity & metabolism, 2020-04, Vol.22 (4), p.622-630

2020

Volltextzugriff (PDF)

Risk of New-Onset Type 2 Diabetes Mellitus in 600,055 Persons after COVID-19: a cohort study

Diabetes, obesity & metabolism, 2022-02, Vol.24 (6), p.1176-1179

2022

Volltextzugriff (PDF)

Fixed-ratio combination therapy for type 2 diabetes: the top ten things you should know about insulin and glucagon-like peptide-1 receptor agonist combinations

Postgraduate medicine, 2018-05, Vol.130 (4), p.375-380

2018

Volltextzugriff (PDF)

Impact of the hepatoselective glucokinase activator TTP399 on ketoacidosis during insulin withdrawal in people with type 1 diabetes

Diabetes, obesity & metabolism, 2022-08, Vol.24 (8), p.1439-1447

2022

Volltextzugriff (PDF)

Erratum. COVID-19 Severity Is Tripled in the Diabetes Community: A Prospective Analysis of the Pandemic's Impact in Type 1 and Type 2 Diabetes. Diabetes Care 2021;44:526-532

Diabetes care, 2022-05, Vol.45 (5), p.1299-1299

2022

Volltextzugriff (PDF)

Response to Comment on Gregory et al. COVID-19 Severity Is Tripled in the Diabetes Community: A Prospective Analysis of the Pandemic's Impact in Type 1 and Type 2 Diabetes. Diabetes Care 2021;44:526-532

Diabetes care, 2021-05, Vol.44 (5), p.e103-e104

2021

Volltextzugriff (PDF)

Adjunct Therapy in Type 1 Diabetes: A Survey to Uncover Unmet Needs and Patient Preferences Beyond HbA1c Measures

Diabetes technology & therapeutics, 2019-06, Vol.21 (6), p.336-343

2019

Volltextzugriff (PDF)

Demographic characteristics and acute complications among adults with type 1 diabetes: Comparison of two multicentre databases from Germany and the United States

Journal of diabetes and its complications, 2021-03, Vol.35 (3), p.107812-107812, Article 107812

2021

Volltextzugriff (PDF)

Immunomodulatory activity of humanized anti-IL-7R monoclonal antibody RN168 in subjects with type 1 diabetes

JCI insight, 2019-12, Vol.4 (24)

2019

Volltextzugriff (PDF)

Continuous positive airway pressure is here to stay

The lancet respiratory medicine, 2024-07, Vol.12 (7), p.507-508

2024

Volltextzugriff (PDF)

Risk of new‐onset type 2 diabetes in 600055 people after COVID‐19: A cohort study

Diabetes, obesity & metabolism, 2022-06, Vol.24 (6), p.1176-1179

2022

Volltextzugriff (PDF)

Differences between patients with type 1 diabetes with optimal and suboptimal glycaemic control: A real‐world study of more than 30000 patients in a US electronic health record database

Diabetes, obesity & metabolism, 2020-04, Vol.22 (4), p.622-630

2020

Volltextzugriff (PDF)

Comment on Gregory et al. COVID-19 Severity Is Tripled in the Diabetes Community: A Prospective Analysis of the Pandemic's Impact in Type 1 and Type 2 Diabetes. Diabetes Care 2021;44:526–532/ Reply

Diabetes care, 2021-05, Vol.44 (5), p.e103

2021

Volltextzugriff (PDF)

MON-LB110 A Phase 2 Evaluation of a Ready-To-Use Liquid Stable Continuous Subcutaneous Glucagon Infusion for the Treatment of Hypoglycemia Associated Autonomic Failure

Journal of the Endocrine Society, 2020-05, Vol.4 (Supplement_1)

2020

Volltextzugriff (PDF)

1 – 25 von 33

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(25)
Mit Volltextzugriff
(22)

Publikationsform

Artikel
(33)

Sprache

Englisch
(33)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(20)
Science & Technology
(20)
Endocrinology & Metabolism
(17)
Diabetes
(14)
Diabetes Mellitus
(14)
Humans
(14)
Hypoglycemia
(10)
Insulin
(10)
Adult
(8)
Glucose
(7)
Diabetic Ketoacidosis
(6)
Female
(6)
Male
(6)
Blood Glucose
(5)
Diabetes Mellitus, Type 1 - Drug Therapy
(5)
Hemoglobin
(5)
Ketoacidosis
(5)
Middle Aged
(5)
Adults
(4)
Blood Pressure
(4)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

COVID-19 Severity Is Tripled in the Diabetes Community: A Prospective Analysis of the Pandemic's Impact in Type 1 and Type 2 Diabetes

Astaxanthin, a natural antioxidant, lowers cholesterol and markers of cardiovascular risk in individuals with prediabetes and dyslipidaemia

Time in Tight Range for Patients With Type 1 Diabetes: The Time Is Now, or Is It Too Soon?

Incidences of Severe Hypoglycemia and Diabetic Ketoacidosis and Prevalence of Microvascular Complications Stratified by Age and Glycemic Control in U.S. Adult Patients With Type 1 Diabetes: A Real-World Study

Risk of new‐onset type 2 diabetes in 600 055 people after COVID‐19: A cohort study

International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors

Past-Month Cannabis Use Among Adults With Diabetes in the U.S., 2021-2022

SGLT2 Inhibition Increases Fasting Glucagon but Does Not Restore the Counterregulatory Hormone Response to Hypoglycemia in Participants With Type 1 Diabetes

Combination SGLT2 Inhibitor and Glucagon Receptor Antagonist Therapy in Type 1 Diabetes: A Randomized Clinical Trial

Continuous Glucose Monitoring Time Below Range Predicts Impaired Epinephrine Response to Hypoglycemia in Patients With Type 1 Diabetes

Efficacy and Safety of the Glucagon Receptor Antagonist RVT-1502 in Type 2 Diabetes Uncontrolled on Metformin Monotherapy: A 12-Week Dose-Ranging Study

Differences between patients with type 1 diabetes with optimal and suboptimal glycaemic control: A real‐world study of more than 30 000 patients in a US electronic health record database

Risk of New-Onset Type 2 Diabetes Mellitus in 600,055 Persons after COVID-19: a cohort study

Fixed-ratio combination therapy for type 2 diabetes: the top ten things you should know about insulin and glucagon-like peptide-1 receptor agonist combinations

Impact of the hepatoselective glucokinase activator TTP399 on ketoacidosis during insulin withdrawal in people with type 1 diabetes

Erratum. COVID-19 Severity Is Tripled in the Diabetes Community: A Prospective Analysis of the Pandemic's Impact in Type 1 and Type 2 Diabetes. Diabetes Care 2021;44:526-532

Response to Comment on Gregory et al. COVID-19 Severity Is Tripled in the Diabetes Community: A Prospective Analysis of the Pandemic's Impact in Type 1 and Type 2 Diabetes. Diabetes Care 2021;44:526-532

Adjunct Therapy in Type 1 Diabetes: A Survey to Uncover Unmet Needs and Patient Preferences Beyond HbA1c Measures

Demographic characteristics and acute complications among adults with type 1 diabetes: Comparison of two multicentre databases from Germany and the United States

Immunomodulatory activity of humanized anti-IL-7R monoclonal antibody RN168 in subjects with type 1 diabetes

Continuous positive airway pressure is here to stay

Risk of new‐onset type 2 diabetes in 600055 people after COVID‐19: A cohort study

Differences between patients with type 1 diabetes with optimal and suboptimal glycaemic control: A real‐world study of more than 30000 patients in a US electronic health record database

Comment on Gregory et al. COVID-19 Severity Is Tripled in the Diabetes Community: A Prospective Analysis of the Pandemic's Impact in Type 1 and Type 2 Diabetes. Diabetes Care 2021;44:526–532/ Reply

MON-LB110 A Phase 2 Evaluation of a Ready-To-Use Liquid Stable Continuous Subcutaneous Glucagon Infusion for the Treatment of Hypoglycemia Associated Autonomic Failure

Suchergebnisse filtern